| Abstract |
Abstract: Background The onset of schizophrenia is characterized by a long course of disease, easy recurrence and poor prognosis, which affects the safety of patients and their families, and also increases the risk of family and social instability. Objective In order to improve the prognosis of patients, this study explored the efficacy of olanzapine combined with transcranial magnetic stimulation in the treatment of schizophrenia and the influence on liver and kidney function indexes of patients. Methods A total of 86 patients with schizophrenia diagnosed according to the International Classification of Diseases (10th Edition) were selected from Shalingzi Hospital of Zhangjiakou City from March 2018 to March 2019 as the study objects. According to the random number table method, patients were divided into the study group (n=43) and the control group (n=43). The study group received olanzapine combined with transcranial magnetic stimulation, and the control group received olanzapine. Both groups were treated for 8 weeks. Positive and Negative Symptom Scale was used to assess patients symptoms, Wechsler Memory Scale was used to assess the cognitive function, and the automatic analyzer was used to detect liver and kidney function indexes before and after treatment. The therapeutic efficacy and incidence of adverse reactions were compared between the two groups. Results After treatment, the scores of psychopathology, positive symptoms and negative symptoms in the study group were lower than those in the control group, with statistically significant differences (t=3.635, 6.836, 9.363; P < 0.05); After treatment, the scores of directed memory, meaningless figure recognition, image free recall, portrait feature recall, associative learning and memory quotient in the study group were lower than those in the control group, with statistically significant differences (t=3.735, 8.458, 4.770, 4.125, 4.849, 7.232; P < 0.05); After treatment, there were no statistically significant differences in liver and kidney function indexes such as alanine aminotransferase, aspartate aminotransferase, creatinine and urea nitrogen between the two groups (t=3.735, 8.458, 4.770, 4.125, 4.849, 7.232; all P > 0.05); The total effective rate by the end of treatment in the study group (76.74%) was higher than that in the control group (55.81%), with statistically significant differences (P < 0.05); There was no statistically significant difference in the incidence of adverse reactions between the two groups by the end of treatment (9.30% vs 13.95%, χ2=0.453, P > 0.05). Conclusions The combination of olanzapine and transcranial magnetic stimulation in patients with schizophrenia can help reduce the symptoms of schizophrenia, improve the cognitive function of patients, and will not damage the liver and kidney function of patients, with excellent therapeutic effect and safety.
|